The highlight of the recent MedAdvisor (ASX:MDR) annual results for FY 2018 was undoubtedly the fact that revenue from continuing operations reached $6.6 million, some 50% higher than last year. To the company’s credit, they highlighted this operational number as well as the more flattering $7.4 million in revenue, once you include R&D grants. It made a statutory loss of $4.5 million.